Jun 29, 2007 by Brian Orelli, PhDThe Phase 2 BluesDrug developer Cytokinetics disappoints investors with failed clinical trials.
Jun 26, 2007 by Brian Orelli, PhDWinners and Losers of Senate Drug BillCould the compromise regarding generics be win-win?
Jun 25, 2007 by Brian Orelli, PhDLeading the Pack of Follow-On Drug MakersIn front of the second group is a good place to be.
Jun 15, 2007 by Brian Orelli, PhDGet Your Uncle To Pay for Your Capital ImprovementsIt's nice to have a very rich uncle.
Jun 13, 2007 by Brian Orelli, PhDEvaluating a One-Trick PonyWhere is pharmaceutical company Onyx headed?
Jun 4, 2007 by Brian Orelli, PhDOXiGENE's Moving AheadOXiGENE reaches a deal with FDA on its lead compound.
May 30, 2007 by Brian Orelli, PhDMedImmune's FDA Roller CoasterThe firm is having its share of ups and downs, courtesy of everyone's favorite government agency.
May 25, 2007 by Brian Orelli, PhDAmylin Sifts for GoldThe biotech mines extra value from its compound library.
May 23, 2007 by Brian Orelli, PhDPharma TV -- All Drugs, All the TimeComing to a television near you?
May 21, 2007 by Brian Orelli, PhDThe Doctor Is on a Roller CoasterIt isn't going to be pretty, but at least Dr. Reddy's sees the profit loss coming.
May 18, 2007 by Brian Orelli, PhDPatents Shine, but Don't Be Blinded by ThemExclusive drug sales will come and go; it's the drugs in the pipeline that drive sales growth.
May 14, 2007 by Brian Orelli, PhDLittle Product, Big ProfitsAbraxis reports increased sales of its nano-sized product.
May 7, 2007 by Brian Orelli, PhDIntrogen's Still Standing -- for NowWith a lack of products, Introgen's burn rate is a key factor for investors to figure out its chance of survival.
May 3, 2007 by Brian Orelli, PhD2 Suitors Are Better Than 1Biosite has two companies vying to acquire it.
Apr 30, 2007 by Brian Orelli, PhDNo Pain for Endo's InvestorsEndo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands.
Apr 27, 2007 by Brian Orelli, PhDMaking Money Off Your CompetitorsAffymetrix is looking appealing with a few new products and potential revenues from an unlikely source.
